vTv Therapeutics posts Q3 net loss of $8.7 million

Reuters11-07

vTv <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts Q3 net loss of $8.7 million

vTv Therapeutics Inc. reported no revenue for the third quarter of 2025, compared to no revenue in the same period of 2024. For the nine months ended September 30, 2025, revenue was zero, compared to $1.0 million for the same period in 2024. Net loss attributable to vTv Therapeutics Inc. for the third quarter of 2025 was $8.7 million, compared to $4.8 million in the prior-year period. For the nine months ended September 30, 2025, net loss was $19.8 million, compared to $14.8 million for the same period in 2024. Research and development expenses increased to $7.0 million for the third quarter of 2025 from $3.2 million in the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $98.5 million, up from $36.7 million at the end of 2024. During the quarter, vTv Therapeutics randomized its first patient in the Phase 3 CATT1 trial, expanded its U.S. patent estate for cadisegliatin, and completed an $80 million private placement financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581043691?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581043691","market":"nz","top_or_hot":-1,"title":"vTv Therapeutics posts Q3 net loss of $8.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posts Q3 net loss of $8.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> reported no revenue for the third quarter of 2025, compared to no revenue in the same period of 2024. For the nine months ended September 30, 2025, revenue was zero, compared to $1.0 million for the same period in 2024. Net loss attributable to vTv Therapeutics Inc. for the third quarter of 2025 was $8.7 million, compared to $4.8 million in the prior-year period. For the nine months ended September 30, 2025, net loss was $19.8 million, compared to $14.8 million for the same period in 2024. Research and development expenses increased to $7.0 million for the third quarter of 2025 from $3.2 million in the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $98.5 million, up from $36.7 million at the end of 2024. During the quarter, vTv Therapeutics randomized its first patient in the Phase 3 CATT1 trial, expanded its U.S. patent estate for cadisegliatin, and completed an $80 million private placement financing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>vTv Therapeutics posts Q3 net loss of $8.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nvTv Therapeutics posts Q3 net loss of $8.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      vTv <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posts Q3 net loss of $8.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VTVT\">vTv Therapeutics Inc.</a> reported no revenue for the third quarter of 2025, compared to no revenue in the same period of 2024. For the nine months ended September 30, 2025, revenue was zero, compared to $1.0 million for the same period in 2024. Net loss attributable to vTv Therapeutics Inc. for the third quarter of 2025 was $8.7 million, compared to $4.8 million in the prior-year period. For the nine months ended September 30, 2025, net loss was $19.8 million, compared to $14.8 million for the same period in 2024. Research and development expenses increased to $7.0 million for the third quarter of 2025 from $3.2 million in the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $98.5 million, up from $36.7 million at the end of 2024. During the quarter, vTv Therapeutics randomized its first patient in the Phase 3 CATT1 trial, expanded its U.S. patent estate for cadisegliatin, and completed an $80 million private placement financing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTVT","symbol_name":"vTv Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6GYXj6:1","article_id":"2581043691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581043691","pubTimestamp":1762464494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"vTv Therapeutics Inc. reported no revenue for the third quarter of 2025, compared to no revenue in the same period of 2024. For the nine months ended September 30, 2025, revenue was zero, compared to $1.0 million for the same period in 2024. Net loss attributable to vTv Therapeutics Inc. for the third quarter of 2025 was $8.7 million, compared to $4.8 million in the prior-year period. For the nine months ended September 30, 2025, net loss was $19.8 million, compared to $14.8 million for the same period in 2024. Research and development expenses increased to $7.0 million for the third quarter of 2025 from $3.2 million in the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $98.5 million, up from $36.7 million at the end of 2024. During the quarter, vTv Therapeutics randomized its first patient in the Phase 3 CATT1 trial, expanded its U.S. patent estate for cadisegliatin, and completed an $80 million private placement financing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTVT":"vTv Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"vTv Therapeutics第三季度净亏损870万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTVT":0.9},"content_text":"vTv Therapeutics posts Q3 net loss of $8.7 million\n    \n\nvTv Therapeutics Inc. reported no revenue for the third quarter of 2025, compared to no revenue in the same period of 2024. For the nine months ended September 30, 2025, revenue was zero, compared to $1.0 million for the same period in 2024. Net loss attributable to vTv Therapeutics Inc. for the third quarter of 2025 was $8.7 million, compared to $4.8 million in the prior-year period. For the nine months ended September 30, 2025, net loss was $19.8 million, compared to $14.8 million for the same period in 2024. Research and development expenses increased to $7.0 million for the third quarter of 2025 from $3.2 million in the third quarter of 2024. As of September 30, 2025, cash and cash equivalents totaled $98.5 million, up from $36.7 million at the end of 2024. During the quarter, vTv Therapeutics randomized its first patient in the Phase 3 CATT1 trial, expanded its U.S. patent estate for cadisegliatin, and completed an $80 million private placement financing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581043691","isCrawlerRequest":true}